闻泰科技宣布:索赔或达80亿美元!积极准备明年一月听证会

Core Viewpoint - The company is actively preparing for a second hearing in January 2026 to assert its rights and seek a resolution regarding the ongoing dispute with Nexperia, emphasizing the need to restore its full rights as a shareholder and legal control over Nexperia [2][7]. Group 1: Legal Actions and Dispute Resolution - The company has initiated multiple legal proceedings in the Netherlands, potentially seeking international arbitration and compensation amounting to $8 billion [2][8]. - The company has expressed willingness to negotiate with Nexperia in the Netherlands to find a collaborative solution, having held initial discussions with independent directors and custodians appointed by the court [2][8]. - The company has submitted a dispute notice on October 15, indicating that if the issue is not resolved within six months, it may pursue international arbitration [8]. Group 2: Supply Chain Stability - In response to Nexperia's suspension of direct wafer supply to its Chinese factory, the company is actively working on "self-rescue" measures to stabilize its supply chain [4][8]. - The company is validating domestic wafer suppliers to fill the supply gap, aiming to complete this process by the first to second quarter of 2026 [4]. - The company has set a target for domestic production to account for 80% of its overall capacity, with the Chinese market representing approximately 50% of global sales [4]. Group 3: Corporate Governance - During the recent shareholder meeting, the company reviewed proposals for expected related-party transactions for 2026 and the appointment of a new independent director, Gan Peizhong, a well-known legal expert [3][5].